
Findings presented at the European Respiratory Society Congress 2026 suggest semaglutide may offer respiratory benefits beyond its approved diabetes and obesity indications.
From a healthcare provider perspective, DIR can affect businesses, patients, and much more.
Today's episode features Jack Mozloom and guests Dr. Kathy Campbell and Bri Morris from NCPA who discuss the Creating Health program and different perspectives on DIR.






